We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+4.42%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$231M
AUM Growth
-$37.1M
Cap. Flow
-$48M
Cap. Flow %
-20.83%
Top 10 Hldgs %
50.4%
Holding
85
New
16
Increased
17
Reduced
31
Closed
20

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$7.59M
2
MRK icon
Merck
MRK
+$5.05M
3
TVTY
Tivity Health, Inc. Common Stock
TVTY
+$3.65M
4
BAX icon
Baxter International
BAX
+$3.3M
5
IQV icon
IQVIA
IQV
+$3.29M

Top Sells

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$9.5M
2
BDX icon
Becton Dickinson
BDX
+$7.34M
3
JNJ icon
Johnson & Johnson
JNJ
+$6.92M
4
UNH icon
UnitedHealth
UNH
+$6.85M
5
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$6.34M

Sector Composition

Rank Sector Weight
1 Healthcare 93.59%
2 Financials 2.32%
3 Real Estate 0.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PBYI icon
26
Puma Biotechnology
PBYI
$404M
$2.41M 1.05%
40,788
+16,088
+65% +$932K
BSX icon
27
Boston Scientific
BSX
$69.5B
$2.38M 1.03%
72,841
-314,857
-81% -$9.5M
COO icon
28
Cooper Companies
COO
$14.1B
$2.22M 0.96%
+37,768
New +$2.16M
CNC icon
29
Centene
CNC
$30.7B
$2.17M 0.94%
+35,222
New +$2.03M
OXFD
30
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$2.02M 0.88%
156,869
-8,300
-5% -$112K
SBRA icon
31
Sabra Healthcare REIT
SBRA
$5.34B
$1.98M 0.86%
90,922
-194,297
-68% -$3.79M
SYNH
32
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$1.84M 0.8%
39,198
-153,202
-80% -$6.34M
REGN icon
33
Regeneron Pharmaceuticals
REGN
$78.5B
$1.83M 0.79%
5,300
+3,100
+141% +$970K
A icon
34
Agilent Technologies
A
$39.1B
$1.82M 0.79%
29,411
+9,411
+47% +$614K
ESRX
35
DELISTED
Express Scripts Holding Company
ESRX
$1.8M 0.78%
23,290
-31,500
-57% -$2.36M
WBA
36
DELISTED
Walgreens Boots Alliance
WBA
$1.75M 0.76%
29,148
-91,075
-76% -$5.86M
MCK icon
37
McKesson
MCK
$100B
$1.71M 0.74%
12,779
+1,256
+11% +$184K
SYK icon
38
Stryker
SYK
$125B
$1.58M 0.69%
+9,360
New +$1.57M
PRAH
39
DELISTED
PRA Health Sciences, Inc.
PRAH
$1.41M 0.61%
+15,068
New +$1.3M
CLVS
40
DELISTED
Clovis Oncology, Inc.
CLVS
$1.39M 0.6%
30,500
-2,600
-8% -$126K
ARRY
41
DELISTED
Array Biopharma Inc
ARRY
$1.37M 0.59%
81,416
+10,016
+14% +$159K
PFE icon
42
Pfizer
PFE
$143B
$1.24M 0.54%
+35,996
New +$1.23M
BHC icon
43
Bausch Health
BHC
$2.58B
$1.09M 0.47%
46,929
-38,271
-45% -$791K
OCUL icon
44
Ocular Therapeutix
OCUL
$1.79B
$964K 0.42%
142,775
-35,686
-20% -$245K
FATE icon
45
Fate Therapeutics
FATE
$286M
$936K 0.41%
82,572
-72,772
-47% -$802K
MNK
46
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$909K 0.39%
+48,725
New +$775K
SRPT icon
47
Sarepta Therapeutics
SRPT
$1.57B
$887K 0.38%
+6,714
New +$633K
FOLD
48
DELISTED
Amicus Therapeutics
FOLD
$851K 0.37%
54,504
-72,496
-57% -$1.1M
NVRO
49
DELISTED
NEVRO CORP.
NVRO
$806K 0.35%
10,096
-605
-6% -$50.2K
PTLA
50
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$786K 0.34%
20,803
-50,697
-71% -$1.94M
1
2
3 4

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, Endurant Capital Management held 85 positions worth $231M, down 14% from $268M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Endurant Capital Management withdrew a net $48M in Q2 2018, closing 20 positions and reducing 31 holdings. Its most notable exit was Envision Healthcare Holdings Inc, an estimated $3.16M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials and Real Estate.

Against the trend, Endurant Capital Management opened a new position in IQVIA worth $3.29M.

  • Endurant Capital Management's largest Q2 2018 buy was IQVIA: 32,945 shares worth $3.29M.
  • Endurant Capital Management added most to Cigna in Q2 2018, an estimated $7.59M increase.
  • Endurant Capital Management's biggest Q2 2018 reduction was Boston Scientific, cutting an estimated $9.5M.
  • Endurant Capital Management fully exited Envision Healthcare Holdings Inc in Q2 2018, selling an estimated $3.16M.
  • Endurant Capital Management's ten largest holdings make up 50% of its $231M portfolio in Q2 2018.
  • Endurant Capital Management opened 16 new positions and closed 20 in Q2 2018.
  • Endurant Capital Management's portfolio value fell 14% quarter-over-quarter to $231M.

Based on Endurant Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.